News and Events

News Release: Corporate Update – APRIL 2017

We started commercial sales activity of the ArtVentive EOS™ in April 2016. From the very beginning, ArtVentive adopted a focused approach to the sales process, development and continuous growth. In the European markets, we market and sell our products through industry distributors. In the U.S, we market directly to selected University Hospitals and private clinics constantly expanding of customer base. We have targeted sales and marketing efforts to interventional radiologists and vascular surgeons with experience using similar catheter-based procedures, such as angioplasty and stenting. Peer-to-peer education is also a key element of our sales strategy.

Our progress to date has been significant where we have achieved 400 – 500% sales growth per quarter. Management is very confident in the sales development and our company’s expansion based on natural organic growth.

Visit ArtVentive at GEST Europe 2017 in Florence

ArtVentive will attend GEST Europe in Florence, Italy from May 31 to June 3 Visit us at booth #9 to learn more about the EOS™ Plug and let us demonstrate its unique ability to immediately occlude blood flow in veins, arteries and tubes in the human...

ArtVentive Concludes Successful Clinical Demonstrations of the Revolutionary EOS™ Occlusion System at SIR 2017 in Washington DC.

The ArtVentive team conducted a series of very successful meetings and workshops at the conference with EOS™ which was featured in several prominent events held at the conference auditorium, the exhibition floor and at hands-on workshops.

EOS™ attracted considerable attention from the audience, primarily interventional radiologists from the US, Europe, Australia and Asia, because it is the only occlusion device that immediately, safely and accurately stops blood flow.

ArtVentive Management Releases Strategic Growth Plan; Reviews Commercial Progress

ArtVentive Medical Group, Inc. (“ArtVentive”) announced today its strategic sales plan for the company’s growth and highlighted recent commercialization progress in the United States and Europe.

Dr, Leon Rudakov, ArtVentive’s founder and Chief Technology Officer, and Bill Olson, newly appointed Chief Executive Officer, identified an innovative sales and marketing strategy for ArtVentive’s revolutionary blood vessel occlusion device EOS™.

Visit ArtVentive at GEST 2016

Join us at the ArtVentive Booth #28 to learn more about the EOS™ Endoluminal Occlusion System at the GEST 2016 U.S. conference in New York.

Conference Dates: 05/05/16 – 05/08/16.